Infusion Reaction | List of Frontiers open access articles

Case Report

Published on 04 Mar 2024

Case report: Pembrolizumab as an alternative to atezolizumab following a severe infusion reaction

in Cancer Immunity and Immunotherapy

Seung Hyuk Lee
Hyeon Jong Kim
Hyun Jin Bang
Su Ji Park
Ji Eun Yu
Seung Woo Jeong
Woo Kyun Bae

Frontiers in Oncology

doi 10.3389/fonc.2024.1273043

3,380 views
1 citation

Review

Published on 31 Oct 2023

Efficacy and safety of immune checkpoint inhibitors for patients with prostate cancer: a systematic review and meta-analysis

in Cancer Immunity and Immunotherapy

Maryam Noori
Shadi Azizi
Aref Mahjoubfar
Farhan Abbasi Varaki
Farimah Fayyaz
Amir-Hossein Mousavian
Davood Bashash
Mehdi Kardoust Parizi
Amir Kasaeian

Frontiers in Immunology

doi 10.3389/fimmu.2023.1181051

7,716 views
18 citations

Case Report

Published on 12 Mar 2025

Case Report: Hemolytic anemia secondary to infliximab treatment in a patient with ulcerative colitis

in Gastroenterology

Gerolamo Bevivino
Patrizio Scarozza
Michela Di Fonzo
Giulia Zerboni
Federico Iacopini

Frontiers in Medicine

doi 10.3389/fmed.2025.1548321

2,735 views

Original Research

Published on 28 Mar 2022

Non HCV-Related Mixed Cryoglobulinemic Vasculitis With Biopsy-Proven Renal Involvement: The Effects of Rituximab

in Hematology

Roberta Fenoglio
Savino Sciascia
Daniela Rossi
Carla Naretto
Mirella Alpa
Dario Roccatello

Frontiers in Medicine

doi 10.3389/fmed.2022.819320

4,748 views
8 citations

Systematic Review

Published on 16 Apr 2025

Efficacy and safety of immune checkpoint inhibitors for brain metastases of non-small cell lung cancer: a systematic review and network meta-analysis

in Pharmacology of Anti-Cancer Drugs

Bin Liu
Jie Chen
Mingqi Luo

Frontiers in Oncology

doi 10.3389/fonc.2025.1513774

3,873 views
3 citations

Original Research

Published on 29 Nov 2024

A novel anti-HER2 monoclonal antibody IAH0968 in HER2-positive heavily pretreated solid tumors: results from a phase Ia/Ib first-in-human, open-label, single center study

in Cancer Immunity and Immunotherapy

Na Song
Yuee Teng
Jing Shi
Zan Teng
Bo Jin
Jinglei Qu
Lingyun Zhang
Ping Yu
Lei Zhao
Jin Wang

Frontiers in Immunology

doi 10.3389/fimmu.2024.1481326

2,938 views
3 citations

Original Research

Published on 07 Mar 2023

Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME)

in Cancer Immunity and Immunotherapy

Tony Reid
Bryan Oronsky
Scott Caroen
Mary Quinn
Jeannie Williams
Pedro Cabrales
Nacer Abrouk

Frontiers in Immunology

doi 10.3389/fimmu.2023.1104753

5,600 views
16 citations

Systematic Review

Published on 11 Nov 2022

Inhibition of the CD47-SIRPα axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data

in Cancer Immunity and Immunotherapy

Ji Son
Rodney Cheng-En Hsieh
Heather Y. Lin
Kate J. Krause
Ying Yuan
Amadeo B. Biter
James Welsh
Michael A. Curran
David S. Hong

Frontiers in Immunology

doi 10.3389/fimmu.2022.1027235

15,976 views
52 citations

Articles

Case report: Pembrolizumab as an alternative to atezolizumab following a severe infusion reaction

Efficacy and safety of immune checkpoint inhibitors for patients with prostate cancer: a systematic review and meta-analysis

Case Report: Hemolytic anemia secondary to infliximab treatment in a patient with ulcerative colitis

Non HCV-Related Mixed Cryoglobulinemic Vasculitis With Biopsy-Proven Renal Involvement: The Effects of Rituximab

Efficacy and safety of immune checkpoint inhibitors for brain metastases of non-small cell lung cancer: a systematic review and network meta-analysis

A novel anti-HER2 monoclonal antibody IAH0968 in HER2-positive heavily pretreated solid tumors: results from a phase Ia/Ib first-in-human, open-label, single center study

Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME)

Inhibition of the CD47-SIRPα axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data